TAp73 is a structural homologue of the pre-eminent tumour suppressor p53. However, unlike p53, TAp73 is rarely mutated, and instead is frequently overexpressed in human tumours. It remains unclear whether TAp73 affords an advantage to tumour cells and if so, what the underlying mechanism is. Here we show that TAp73 supports the proliferation of human and mouse tumour cells. TAp73 activates the expression of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP). By stimulating G6PD, TAp73 increases PPP flux and directs glucose to the production of NADPH and ribose, for the synthesis of macromolecules and detoxification of reactive oxygen species (ROS). The growth defect of TAp73-deficient cells can be rescued by either enforced G6PD expression or the presence of nucleosides plus an ROS scavenger. These findings establish a critical role for TAp73 in regulating metabolism, and connect TAp73 and the PPP to oncogenic cell growth.
TAp73 is a structural homologue of the pre-eminent tumour suppressor p53. However, unlike p53, TAp73 is rarely mutated, and instead is frequently overexpressed in human tumours. It remains unclear whether TAp73 affords an advantage to tumour cells and if so, what the underlying mechanism is. Here we show that TAp73 supports the proliferation of human and mouse tumour cells. TAp73 activates the expression of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP). By stimulating G6PD, TAp73 increases PPP flux and directs glucose to the production of NADPH and ribose, for the synthesis of macromolecules and detoxification of reactive oxygen species (ROS). The growth defect of TAp73-deficient cells can be rescued by either enforced G6PD expression or the presence of nucleosides plus an ROS scavenger. These findings establish a critical role for TAp73 in regulating metabolism, and connect TAp73 and the PPP to oncogenic cell growth.
p73 is a member of the p53 family 1 . Whereas the importance of p53 in tumour suppression is firmly established 2, 3 , p73 plays a complex role in tumorigenesis that is still not well understood [4] [5] [6] [7] . p73 is expressed in two main isoform classes (TAp73 and Np73) with apparently distinct functions [4] [5] [6] [7] ( Supplementary Fig. S1a ). TAp73 isoforms, similar to p53, contain an amino-terminal transactivation domain. TAp73 can activate p53-target genes and induce apoptosis or cell-cycle arrest. In contrast, Np73 lacks the transactivation domain but retains DNA-binding and oligomerization domains. Np73 is able to exert a dominant-negative effect on TAp73, as well as other p53 family members, through the formation of inactive hetero-oligomeric complexes or competition for promoter binding.
Unlike p53-deficient mice, which seem developmentally normal but highly prone to spontaneous tumours 8, 9 , mice with total p73 loss have profound defects in the immune and nervous systems but no increases in tumour incidence 10 . However, total p73 loss cooperates with p53 loss to further promote tumour formation in a context-dependent manner [11] [12] [13] . TAp73-specific knockout mice exhibit partial embryonic lethality, infertility and a marked increase in spontaneous and carcinogen-induced tumours 14 . These phenotypes are probably due, in part, to genomic instability in the absence of TAp73 (refs 14,15) . In contrast, Np73 deficiency in mice leads to increased DNA damage signalling and p53-dependent apoptosis 16 , indicating a role for Np73 in the suppression of the p53 response. These observations support a model in which TAp73, like p53, suppresses tumorigenesis, whereas Np73 promotes it.
Nevertheless, in contrast to p53, which is the most frequently mutated gene in human tumours, TAp73 is rarely mutated in these tumours 4, 6, 7 . An analysis of ∼1,500 human tumours indicated that less than 0.2% harboured a mutant p73 (either isoform class), as opposed to over 50% with a mutant p53 (ref. 4) . Instead, TAp73 is frequently overexpressed, along with Np73, in a wide range of human cancers 6, 7 . The conspicuous absence of TAp73 mutations and prevalence of TAp73 upregulation suggest that TAp73 may afford proliferative advantages to tumour cells.
The metabolism in tumour cells is markedly reprogrammed to enable robust biosynthesis and antioxidant defence [17] [18] [19] . Although the generation of macromolecules is an intuitive requirement for tumour cell proliferation, recent evidence also supports the critical importance of ROS detoxification in oncogenic growth. Tumour cells commonly encounter high oxidative stress due to the effect of oncogenic mutations and their microenvironment 18, 20, 21 . Although moderate and transient elevation in ROS is implicated in proliferation 22, 23 , high and persistent elevation in ROS damages protein, DNA and other cellular components and poses a continuous threat to the viability of tumour cells. The PPP is a major glucose metabolic pathway important for meeting the cellular demands of biosynthesis and antioxidant defence. It provides cells with ribose-5-phosphate (R5P) for de novo synthesis of RNA and DNA, and 
d. (n = 3 independent experiments). (b) Independent TAp73
+/+ and TAp73 −/− MEF cells were injected subcutaneously in nude mice as described previously 42 . Shown are the average weights of the tumours (mean ± s. with the reducing equivalent NADPH for reductive biosynthesis (for example, the synthesis of lipids and deoxyriboses) and antioxidant defence ( Supplementary Fig. S2a ). The pacesetter of the PPP is G6PD, which catalyses the first committing step of this pathway. Here we investigate TAp73 in cell proliferation and identify a critical role for TAp73 in promoting biosynthesis and antioxidant defence through the induction of G6PD expression.
RESULTS

TAp73 supports tumour growth
To investigate the role of TAp73 in tumour cell proliferation, we used E1A/Ras V12 -transformed mouse embryonic fibroblast (MEF) cells with wild-type (+/+) or homozygous disruption of (−/−) TAp73 (ref. 14).
Interestingly, TAp73
−/− MEF cell lines proliferated significantly slower than TAp73 +/+ MEFs ( Fig. 1a and Supplementary Fig. S1b ). To investigate the role of TAp73 in tumour formation, we injected TAp73 −/− and TAp73 +/+ MEF cells into immuno-compromised mice. TAp73 −/− MEF cells gave rise to much smaller tumours than TAp73 +/+ MEF cells did ( Fig. 1b and Supplementary Fig. S1c ). To extend these analyses to human tumour cells, we stably knocked down TAp73 in human osteosarcoma U2OS cells using small hairpin RNA (shRNA). This significantly reduced the ability of U2OS cells to proliferate in culture and to establish tumours in a xenograft mouse model (Fig. 1c,d and Supplementary Fig. S1d ). These observations suggest that TAp73 is required for optimal cell proliferation and tumour formation.
For comparison, we also investigated the role of Np73 in tumour cell proliferation using E1A/Ras V12 -transformed Np73 −/− MEFs and the matched Np73 +/+ MEFs (ref. 16 ). We observed that loss of Np73 resulted in a decrease in cell proliferation ( Supplementary  Fig. S1e ,f), consistent with a role for Np73 in tumour growth 16 .
TAp73 enhances the PPP
We investigated the mechanism by which TAp73 promotes proliferation. Our recent studies have shown that p53 inhibits the PPP (ref. 24) .
We assessed whether TAp73 has any regulatory effects on the glucose flux through this pathway. TAp73 +/+ and TAp73 −/− MEF cells were cultured in medium containing [2- 13 C]glucose, and the PPP flux was measured on the basis of the rate of glucose consumption and 13 C labelling patterns in lactate determined by nuclear magnetic resonance (NMR) spectroscopy 24, 25 . Of note, TAp73 deficiency reduced the PPP flux by ∼50%, whereas Np73 deficiency had no effect (Fig. 2a,b) , suggesting that TAp73, but not Np73, enhances the PPP flux.
The rate-limiting enzyme of the PPP is G6PD, which catalyses the conversion of glucose-6-phosphate to 6-phosphate-gluconolactone ( Supplementary Fig. S2a ) 26 . We assayed G6PD activity in TAp73
and TAp73 −/− MEF cells. Importantly, TAp73 −/− MEFs showed a strong reduction (∼45-55%) in overall G6PD activity compared with TAp73 +/+ MEFs. However, no significant difference in G6PD activity was observed between Np73 −/− and Np73 +/+ MEFs (Fig. 2c,d ). Correlating with these results, deficiency of TAp73, but not of Np73, led to strong reduction in G6PD messenger RNA levels (Fig. 2c,d ). 
P <0.005 P < 0.0124 P < 0.006 P < 0.007 To ascertain the stimulatory effect of TAp73 on G6PD, we used small interfering RNA (siRNA) to knock down p73 in U2OS cells. This led to a noticeable decline in both the activity and expression levels of G6PD ( Fig. 2e and Supplementary Fig. S2b ). Introducing an siRNA-resistant form of TAp73 in p73-siRNA-treated cells largely restored G6PD expression ( Supplementary Fig. S2b ), underscoring the specificity of the siRNA. Likewise, on p73 knockdown, G6PD activity and expression were reduced in three isogenic human colorectal HCT116 cell lines, which were wild-type for p53 and its target gene p21 (p53 (Fig. 2f-h) . A strong effect of p73 knockdown on G6PD was also observed in the normal human diploid fibroblast IMR90 cells (Fig. 2i ).
G6PD is a target gene for TAp73
To examine the p73 isoform-specific effect on G6PD expression, we knocked down either total p73 or Np73 using siRNAs in HeLa cells, which express relatively high levels of Np73, compared with other cell lines tested ( Supplementary Fig. S2c ). Silencing total p73, but not Np73, led to a noticeable reduction in G6PD levels ( Supplementary  Fig. S2d ). We also knocked down TAp73 using shRNA, which strongly decreased G6PD expression in U2OS, IMR90 and human lung cancer H1299 cells (Fig. 3a,b and Supplementary Fig. S2e,f) . Conversely, enforced expression of a TAp73 isoform (TAp73α), but not the corresponding Np73 isoform ( Np73α), augmented G6PD expression ( Fig. 3c and Supplementary Fig. S2g ). Unlike TAp73, neither overexpression nor knockdown of p53, or the other p53 family member p63, affected G6PD levels (Fig. 3a,c and Supplementary Fig. S2f,g ). Together, these results indicate that TAp73 specifically enhances the expression of G6PD.
p73 is activated by DNA damage signals [27] [28] [29] [30] . When TAp73 +/+ MEFs were treated with the genotoxic agent etoposide (ETP), TAp73 was stabilized and G6PD expression was elevated (Fig. 3d) . In contrast,
ETP reduced G6PD expression in TAp73
−/− MEFs (Fig. 3d) . When IMR90 cells were treated with ETP, TAp73 was also stabilized, and both the G6PD mRNA and protein were significantly increased. However, in cells devoid of p73, G6PD failed to accumulate on DNA damage (Fig. 3e) . Together, these results suggest that TAp73 stimulates the expression of G6PD both at basal levels in unstressed cells and when TAp73 is stabilized by DNA damage. In addition, a TAp73-independent mechanism might reduce G6PD expression on DNA damage, but TAp73 can override this effect.
To determine whether TAp73 is a transcriptional activator for the G6PD gene, we analysed the human G6PD gene sequence for potential p53 family protein response elements, which share the consensus sequence of 5 -RRRCWWGYYY-(0-13 base pair (bp) spacer)-RRRCWWG YYY-3 (where R is a purine, Y a pyrimidine, and W an A or T; ref. 31) . One potential response element was identified in the second intron of G6PD (Fig. 3f) . To investigate the binding of p73 to this response element, we performed chromatin immunoprecipitation (ChIP) assays. In the p53-wild-type A549 cells, endogenous p73 bound to the response element region of the G6PD gene; the binding was strengthened when cells were treated with the DNA damaging agent doxorubicin (DOX), which stabilized the p53 family proteins ( Fig. 3g and Supplementary Fig. S2h ). We observed no association between endogenous p53 or p63 and the G6PD gene under these conditions (Fig. 3g) , even though p53 bound strongly to its target gene Puma as expected (Fig. 3i) . Similarly, when H1299 cells were transfected individually with green fluorescence protein (GFP) fusions of p53 family members, GFP-TAp73α, but not GFP-p53 or GFP-TAp63α, associated with the G6PD genomic DNA (Fig. 3h) .
To evaluate whether the response element within G6PD confers TAp73-dependent transcriptional activation, we cloned DNA fragments containing the wild-type response element or a mutant response element into the promoter region of a firefly luciferase reporter plasmid. Both TAp73α and TAp73β were able to induce luciferase expression from the wild-type reporter plasmid but not from the mutant reporter plasmid (Fig. 3j,k) . Consistent with previous observations 32, 33 , TAp73β had higher transactivation activity when compared with TAp73α (Fig. 3j) . In contrast, p53, TAp63a and Np73 failed to activate the wild-type response-element-responsive luciferase ( Fig. 3j and Supplementary Fig. S2i ). These results suggest that TAp73, not p53 or TAp63, binds to the consensus p53 family response element within the second intron of G6PD and activates G6PD expression.
Tumour-derived p53 mutants may impair the function of TAp73 (ref. 34). We investigated two common p53 mutants, R175H and R273H. Overexpression of either mutant failed to suppress G6PD expression regardless of whether TAp73 was co-expressed ( Supplementary Fig. S2j ). Also, knocking down these mutant forms of p53 did not affect the expression of G6PD (Fig. 3l) . Thus, mutant p53 proteins may not impede the ability of TAp73 to stimulate G6PD expression.
p73 regulates NADPH homeostasis through G6PD
The PPP is a primary source of cellular NADPH (ref. 35) . In MEF cells, the lack of TAp73, but not Np73, noticeably reduced NADPH levels and increased NADP + /NADPH ratios ( Fig. S3e ). To determine whether the effect of TAp73 on NADPH is mediated by G6PD, we stably overexpressed G6PD in TAp73 −/− MEF cells and p73-depleted U2OS cells with retrovirusmediated gene transfer. This restored the levels of G6PD expression and activity and reduced the NADP + /NADPH ratios in these cells (Fig. 4e-h) . Therefore, TAp73 maintains cellular NADPH content by stimulating the expression of G6PD.
A role for p73 in antioxidative defence
G6PD plays an important role in antioxidant metabolism by producing NADPH to regenerate reduced glutathione 36, 37 . Treatment of TAp73 +/+ MEFs with a G6PD-specific siRNA or the G6PD inhibitor dehydroepiandrosterone (DHEA) led to the accumulation of ROS ( Fig. 5a and Supplementary Fig. S4a,b) . Similarly, when G6PD was depleted in U2OS and IMR90 cells, ROS levels markedly rose ( Fig. 5b and Supplementary Fig. S4c ). Importantly, TAp73
−/− MEFs also exhibited high ROS levels, similar to G6PD siRNA or DHEA-treated TAp73 +/+ MEFs. In TAp73 −/− MEFs, treatment with DHEA or G6PD siRNA only slightly increased ROS ( Fig. 5a and Supplementary  Fig. S4a,b) . Similarly, U2OS and IMR90 cells devoid of p73 contained abundant ROS, and knockdown of G6PD in these cells raised ROS only slightly higher ( Fig. 5b and Supplementary Fig. S4c ).
We next examined the effect of TAp73 on cellular capacity to withstand oxidative stresses. Compared with TAp73 +/+ cells, TAp73 −/− MEFs were markedly more sensitive to hydrogen peroxide (H 2 O 2 ) treatment ( Fig. 5c and Supplementary Fig. S4d ). Inhibition of G6PD by siRNA or DHEA reduced the survival of TAp73 −/− cells and especially TAp73
+/+ cells, minimizing the difference between these two cell types ( Fig. 5c and Supplementary Fig. S4d ). Knockdown of p73 in U2OS also sensitized these cells to H 2 O 2 treatment, and silencing G6PD diminished the difference between these cells and the control cells ( Supplementary Fig. S4e ).
To ascertain that the sensitivity of TAp73-deficient cells to oxidative stresses is due to the reduction in G6PD expression, we investigated the effect of G6PD expression in these cells. Forced expression of G6PD in TAp73 −/− MEFs and p73-depleted U2OS cells reduced the ROS content (Fig. 5d,e) . It also significantly enhanced the survival of p73-depleted cells in the presence of H 2 O 2 ( Fig. 5f ). Together, these data suggest that TAp73 plays a role in protecting against oxidative stress and that this effect of TAp73 is mediated, at least in part, by G6PD.
p73 regulates DNA biosynthesis and cell senescence
The PPP provides NADPH and ribose, both of which are important synthetic precursors for nucleic acids. We compared DNA synthesis in TAp73 +/+ and TAp73 −/− MEFs using 5-bromo-2 -deoxyuridine (BrdU) incorporation assays. DNA synthesis was sharply reduced in TAp73 −/− MEFs, when compared with TAp73 +/+ MEFs (Fig. 6a) . Likewise, DNA synthesis slowed down when p73 was silenced in U2OS and various HCT116 cells (Fig. 6b,c and Supplementary Fig. S5a,b) . In each cell type, treatment with DHEA or G6PD siRNA inhibited DNA synthesis in TAp73-depleted cells and especially in control cells, lessening the difference between them (Fig. 6a-c and Supplementary Fig. S5a,b) .
We also examined the effect of p73 on cell-cycle progression. Knockdown of p73 led to a reduction in the number of cells in S phase and an increase in the number of cells in G1 and G2/M phases. This effect was independent of the status of p53 and the p53/p73-inducible cell-cycle regulator p21. Knockdown of G6PD diminished the difference in DNA synthesis between p73-depleted cells and control cells (Fig. 6d and Supplementary Fig. S5c,d) . Conversely, forced expression of G6PD almost completely restored DNA synthesis in p73-depleted U2OS cells (Fig. 6e) . These results suggest that TAp73 stimulates DNA synthesis through G6PD.
The loss TAp73 in mouse cells accelerates cellular senescence 38 . We investigated the role of G6PD in this process using human IMR90 cells, a well-established model for senescence. When compared with cultures treated with control siRNA, IMR90 cultures treated with p73 siRNA showed a noticeable increase in the number of cells with senescence phenotypes, including flat morphology and the expression of the senescence-associated β-galactosidase (SA-β-gal; Fig. 6f and Supplementary Fig. S5e ). Knockdown of G6PD increased the number of senescent cells strongly in control cultures, but relatively moderately in p73-depleted cultures, reducing the difference between these two groups ( Supplementary Fig. S5e ). More importantly, overexpression of G6PD effectively reversed the induction of senescence in p73-depleted cultures (Fig. 6f) . These data suggest that the lack of TAp73 induces senescence in IMR90 cells at least partially due to the downregulation of G6PD.
p73 enhances cell proliferation through G6PD
Silencing p73 strongly impeded cell growth in various cell lines, including MEFs, U2OS and isogenic HCT116 cell lines (Figs 1a,c and 7a, and Supplementary Figs S1b,d and S6a-c). Growth delay due to p73 downregulation also occurred in p53 −/− HCT116 cells ( Supplementary  Fig. S6b ), indicating a requirement for p73 in cell growth regardless of the status of p53. Depletion of G6PD reduced the growth rate in control cells and especially in TAp73 knockdown cells (Fig. 7a and Supplementary Fig. S6a-c) . Conversely, enforced expression of G6PD partially restored cell growth in p73 knockdown U2OS cells and TAp73 −/− MEF cells but had a minimal effect on control cells (Fig. 7b,c  and Supplementary Fig. S6d-h) . We examined whether the growth-stimulatory effect of TAp73 is related to both a decrease in ROS and an increase in intracellular nucleotides, two main outcomes of the PPP flux. We cultured TAp73 +/+ and TAp73 −/− MEF cells in medium containing the ROS scavenger N -acetyl-l-cysteine (NAC), four ribonucleosides (A, G, U and C) plus four deoxynucleosides (dA, dG, dT and dC), or both. Nucleosides in culture medium can be taken up by cells and converted to the corresponding nucleotides, thus bypassing the requirement for de novo ribose synthesis 39, 40 . Importantly, in the presence of both NAC and nucleotides, but neither individually, TAp73 −/− MEFs grew nearly as well as TAp73 +/+ MEF cells (Fig. 7d) . Moreover, combination treatment with NAC and nucleotides rescued the growth of TAp73 −/− MEFs stably overexpressing G6PD or vector control, but to lesser extents when compared with TAp73 −/− MEFs ( Supplementary  Fig. S6e-h ). These results suggest that TAp73 promotes cell proliferation at least partially through upregulating G6PD, which leads to simultaneous reduction of ROS and enhancement of ribose synthesis.
Analysis of G6PD expression and metastasis status of a large number of primary breast tumours revealed that increasing G6PD expression was significantly correlated with the risk of metastasis ( Supplementary  Fig. S7a,b) . To evaluate the role of G6PD in tumour formation, we injected immuno-compromised mice with U2OS cells or TAp73 +/+ MEF cells expressing G6PD siRNA or control siRNA. G6PD-siRNAexpressing cells generated much smaller tumours when compared with control cells (Fig. 7e,g and Supplementary Fig. S7d ). Conversely, reintroduction of G6PD partially restored tumour formation by TAp73 −/− MEFs ( Fig. 7f and Supplementary Fig. S7c ). We also tested the effect of NAC on the growth of TAp73-and G6PD-deficient tumour cells. In agreement with cell proliferation results, NAC alone failed to restore the growth of tumours derived from either TAp73 −/− MEFs or G6PD-depleted MEFs (Fig. 7g and Supplementary Fig. S7d ).
DISCUSSION
The present study indicates that TAp73 promotes G6PD expression and PPP flux, enhancing biosynthesis and ROS detoxification. Metabolic reprogramming in tumour cells is altered to meet the demand for producing macromolecules and minimizing oxidative damage [17] [18] [19] . Both require NADPH, and it has been proposed that NADPH production may be a rate-liming step in cell proliferation 17, 18 . The production of NADPH seems to be tightly controlled by oncogenes and tumour suppressors. For instance, the oncogene K-Ras stimulates NADPH production in pancreatic cancer cells by enhancing the flux through malic enzyme 1, a cytoplasmic isoform of the NADPHgenerating malic enzymes 41 . In contrast, p53 inhibits the expression of all three malic enzymes that are localized either in the cytoplasm or in the mitochondria 42 . The PPP is not only a major source for NADPH but also highly responsive to oxidative stress 37, 43 . G6PD is a common target for directly adjusting PPP flux. It is allosterically activated by its substrate NADP + and inhibited by its product NADPH. This homeostatic regulation ensures that the PPP is upregulated when more NADPH is needed 26 . The stimulation of G6PD expression by TAp73 may represent a major mechanism that modulates G6PD expression. The TAp73-G6PD pathway is engaged by DNA damage signals (Fig. 3) , probably increasing the supply of NADPH and ribose for DNA repair. We found that G6PD overexpression partially restores the growth of TAp73 −/− MEF cells and p73-depleted U2OS cells. This suggests that, at least in these cells, other TAp73 targets may contribute to its proliferative function. A recent study revealed a role for TAp73 in regulating cytochrome c oxidase subunit 4 (Cox4i1), a subunit of the complex IV of the mitochondrial electron transport chain 38 . By maintaining levels of G6PD as well as Cox4i1, TAp73 likely plays a pre-eminent role in antioxidant response in both unstressed and stressed cells.
Nevertheless, ROS scavengers alone cannot rescue the proliferative defects of TAp73-deficient cells. Rather, both ROS scavengers and nucleosides are needed (Fig. 7) . These observations suggest that TAp73 promotes nucleotide synthesis as well as antioxidant defence, and that the PPP may be a main proliferative target of TAp73. Previous studies showed that on overexpression, TAp73 could activate certain p53 target genes involved in apoptosis or cell-cycle arrest. Yet, the physiological function of TAp73 is probably determined by its endogenous levels of expression, its interplay with the N isoforms, and its regulation by upstream factors. Despite high similarity among p53 family members in the DNA-binding domain, TAp73 alone is able to induce G6PD expression, although the mechanism underlying this selectivity remains to be determined (Fig. 3) . Moreover, Np73 and tumour-associated p53 mutants do not seem to inhibit this function of TAp73 (Fig. 3) . These observations support the notion that G6PD is a high-affinity, physiologically relevant target of TAp73, and that tumour cells benefit from TAp73 upregulation even in the presence of elevated Np73 or mutated p53 proteins.
The critical role of TAp73 in cell proliferation raises the question of why TAp73-deficient mice show increased tumour formation. An explanation may be that extensive genomic instability associated with congenital loss of TAp73 outweighs any proliferative defects in these mice by facilitating the accumulation of oncogenic mutations. It is noteworthy that the function of TAp73 in maintaining genomic stability seems to be cell type specific, as it operates in lung fibroblasts but +/+ and TAp73 −/− MEF cells (1×10 6 ) expressing G6pd siRNA or control siRNA were individually injected subcutaneously into the dorsal flanks of the eight nude mice. Half were given water without NAC and the other half were given water with 40 mM NAC throughout the experiment. Tumour weights (mean±s.d., n = 8 mice in each group) were measured 3 weeks after inoculation.
not in thymic cells, and that TAp73
−/− mice primarily develop lung adenocarcinomas 14 . The role of TAp73 in G6PD expression, on the other hand, is observed in different cell types that have been tested in the present study. Rare mutations and prevalent upregulation of TAp73 in a variety of human tumours suggest that human tumour cells opt for the powerful and probably ubiquitous proliferative advantages conferred by TAp73.
Accumulating evidence indicates that PPP flux is enhanced in tumour cells either directly or indirectly. p53 suppresses the PPP through a direct interaction with G6PD. This activity is lost in tumour-derived p53 mutants 24 . PKM2, an isoform of pyruvate kinase that catalyses the last step in glycolysis, is widely expressed in tumour cells. PKM2 has a low K m for its substrate, leading to the build-up of glycolytic intermediates for alternative pathways including the PPP (ref. 44) . The direct regulation of PPP by two members of the p53 family, as well as indirectly through other mechanisms, underscores both its importance in tumorigenesis and its potential as a therapeutic target.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary Information is available in the online version of the paper
METHODS
Antibodies and reagents. Antibodies against the following proteins/epitopes
were used in this study with the company, catalogue number, and dilution or concentration indicated: GFP (Clontech Laboratories, Mountain View; 632381; 1:4,000), actin (Sigma-Aldrich; A2066; 1:4,000), Flag (Sigma, F3165, 1:4,000), p53 (DO-1) (Santa Cruz Biotechnology; sc-126 HRP; 1:1,000), p73 (Imgenex; IMG-259A; 1:1,000) (Bethyl Laboratories; A300-126A; 1:1,000) (Sigma, SAB4300354, 1:1,000), mouse p73 (Santa Cruz, sc-7238, 1:500) (Cell Signaling Technology; 4300354; 1:1,000), G6PD (Sigma, HPA000834, 1:3,000), p21 (Cell Signaling, 2947, 1:1,000) and fluorescein isothiocyanate (FITC)-labelled anti-BrdU antibody (BD Bioscience Pharmingen; 556028; 10 µM). Anti-p63 antibody was provided by C. Chen 45 . The following reagents were purchased from Sigma: glucose-6-phosphate (G6P), 6-phosphogluconate (6PG), β-nicotinamide adenine dinucleotide 2 -phosphate (NADP + ), β-nicotinamide adenine dinucleotide 2 -phosphate, reduced (NADPH), etoposide (ETP), doxorubicin (DOX), N -acetylcysteine (NAC), propidium iodide (PI), dihydroepiandrosterone (DHEA), crystal violet (CV), hydrogen peroxide (H 2 O 2 ), 2 , 7 -dichlorofluorescein diacetate (DCF) and bromodeoxyuridine (BrdU).
Cell culture and gene knockdown with shRNA and siRNA. HCT116 cells and MEF cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Life Technologies), and when indicated, in minimum essential medium Eagle with ribonucleosides and deoxyribonucleosides (Sigma, M8042). TAp73 −/− , Np73 −/− , and the corresponding wild-type MEFs have been previously described 14, 16 . U2OS cells were maintained in McCoy's 5A Medium, IMR90 cells in MEMα medium, and H1299 cells in RPMI1640 medium (Life Technologies). All mediums, if not specifically described, were supplemented with 10% fetal bovine serum (FBS).
Expression plasmids for shRNAs were made in a pLKO.1-puro vector. The targeted sequences were: p53, 5 -GACTCCAGTGGTAATCTAC-3 (ref. siRNAs were transfected into cells using Lipofectamine RNAiMAX transfection agent (Invitrogen) following the manufacturer's instruction. Stable shRNA transfectants were selected in medium containing 1 µg ml −1 puromycin (Calbiochem, catalogue number 540222) as previously described 48 .
Semi-quantitative PCR with reverse transcription and quantitative realtime PCR. Total RNA was isolated from cells by TRIzol reagent (Invitrogen, catalogue number 15596018) and 2 µg RNA of each sample was reversed to cDNA by the First-strand cDNA Synthesis System (Marligen Biosciences, catalogue No. 11801). cDNA (0.2 µg) of each sample was used as a template to perform PCR. The primer pairs for human genes were: G6PD, 5 -ATGGCAGAGCAGGTGGCCCT-3 and 5 -TCATGCAGGACTCGTGAATG-3 ; β-actin, 5 -GACCTGACTGACTACCTCATGAAGAT-3 and 5 -GTCACACTTCATG-ATGGAGTTGAAGG-3 ; p53, 5 -CACGAGCTGCCCCCAGG-3 and 5 -TCAGTCG-ACGTCTGAGT-3 ; human p63, 5 -ACATGAATGGACTCAGCCCC-3 and 5 -TCACTCCCCCTCCTCTTTGAT-3 ; TAp73, 5 -ATGGCCCAGTCCACCGCCACC-3' and 5 -TCGAAGGTGGAGCTGGG-3 . Primers for mouse genes were: G6pd, 5 -ATGGCAGAGCAGGTGG-3 and 5 -CTCCTCCAGCTTAGGTC-3 ; Actb, 5 -ACTACATTCAATTCCATC-3 and 5 -CTAGAAGCACTTGCGGTG-3 .
G6PD enzyme activity. G6PD enzyme activity was determined as described previously 49 . The combined activity of G6PD and 6-phosphogluconate dehydrogenase (6PGD), the second enzyme of the PPP that also produces NADPH, was determined by the rate of conversion of NADP + to NADPH in the presence of glucose-6-phosphate (G6P). 6PGD activity was measured by the conversion of NADP + to NADPH in the presence of 6-phosphogluconate (6PG). G6PD activity was calculated by subtracting 6PGD from the combined activity. The reaction buffer contained 50 mM Tris (pH 8.1) and 1 mM MgCl 2 , and substrate concentrations were: G6P (200 µM) and 6PG (200 µM) and NADP + (100 µM). Enzyme activities were normalized on the basis of protein concentration, which was determined by a Bio-Rad protein assay kit (Bio-Rad, catalogue number 500-0006). The data are expressed in arbitrary absorption units.
Chromatin immunoprecipitation and reporter assays.
To identify potential p53 family protein response elements, we scan the G6PD gene using the Genomatix Promoter Inspector Program (Genomatix, software, http://www.genomatix.de). For chromatin immunoprecipitation assays, cells were crosslinked with 1% formaldehyde for 15 min at room temperature and crosslinking was stopped by the addition of 125 nM glycine (final concentration). Cell lysates were sonicated to generate DNA fragments with an average size below 1,000 bp and immunoprecipitated with the indicated antibodies. Bound DNA fragments were eluted and amplified by PCR. Primer pairs were: g6pd, 5 -CCCTACTGTCCGTCTTACCTC-3 (+6164/ + 6185) and 5 -CTCTCACTGCTGCACCCTTC-3 (+6643/ + 6663); puma, 5 -TGGCCTTGTGTCTGTGAGTAC-3 ; and 5 -GGACAAGTCAGGACTTGCAGG-3 (ref. 47).
For reporter assay, the G6PD genomic fragments (+6164-+6663) containing either the wild-type (5 -GGTCATGAGCAAACATGACC-3 ) or mutant (GGTTATTAGCAAATATTACC, with mutated nucleotides underlined) p73-binding region were cloned into pGL3-basic vector (Promega, catalog No: E1751). Luciferase reporter assays were performed as described previously 42 . Briefly, the reporter plasmids were transfected into p53-null H1299 cells together with a Renilla luciferase plasmid and increasing amounts of plasmids expressing p53 family proteins. Twenty-four hours after transfection, the luciferase activity was determined using a dual Luciferase Assay System (Promega, catalogue number: E1910). Transfection efficiency was normalized on the basis of the Renilla luciferase activity.
NADPH and ROS levels. NADPH levels and NADP + /NADPH ratios were determined using the NADP + /NADPH Quantification kit (BioVision, catalogue number: K347). ROS levels were analysed as described previously 50 . Briefly, cells were incubated at 37 • C for 30 min in phosphate buffered saline (PBS) containing 10 µM 2 , 7 -dichlorodihydrofluorescein diacetate (H2-DCFDA). Cells were then washed twice with PBS, treated with trypsin, and re-suspended in PBS. Fluorescence signal was immediately measured using a FACScan Flow Cytometer (Becton Dickinson).
PPP fluxes. The flux of the oxidative PPP was measured on the basis of the rate of glucose consumption and the ratio of 13 C incorporated into carbon 2 (generated by glycolysis) and carbon 3 (generated by the PPP) of lactate determined by NMR spectroscopy as described previously 24, 51 .
Analysis of cell-cycle disruptions. Cells were washed with PBS twice and fixed with 75% ethanol overnight at −20 • C. Cells were then treated with 0.1% Triton X-100 and 50 µg ml −1 RNase A for 30 min at 37 • C followed by PI staining. Cell-cycle distribution was analysed using a FACScalibur flow cytometer (BD Biosciences). The data were analysed using Flow Jo software (Tree Star).
BrdU incorporation assay. Cells were treated with G6PD siRNA or control siRNA. After the indicated times, cells were pulse-labelled with BrdU (10 µM final concentration) for 1 h and analysed by anti-BrdU immunostaining as described previously 52 . In brief, BrdU-labelled cells were washed with PBS and fixed sequentially with 2% paraformaldehyde and 70% ethanol at 4 • C. Afterwards, cells were permeabilized with 0.2% Triton X-100 and washed with TBS. DNA was then denatured in 4N HCl-0.2% Triton X-100 for 2 h followed by sequential staining with anti-BrdU antibody and FITC-labelled BrdU-specific antibody. The images were acquired with an Olympus DP71X microscope (Olympus) and BrdU-positive cells were counted. The FITC signal was converted to a red colour for better visualization.
Xenograft tumour models. The xenograft study was performed as described previously 42 . Briefly, cells were injected subcutaneously into the flanks of 4-to 5-wk-old athymic Balb-c nu/nu male mice (Taconic Farms). Three mice in total were used for each treatment in Figs 1b,d and Fig. 7e. Four mice (Fig. 7f ) and eight mice (Fig. 7g) were used for each treatment. Tumour growth was evaluated at 2 or 3 weeks post-injection as indicated. All animal experiments were performed in accordance with relevant guidelines and regulations and were approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC).
Senescence-associated SA-β-gal activity. The SA-β-gal activity in cultured cells was determined using a Senescence Detection Kit (BioVision, catalog No: K320) following the manufacturer's instructions. Percentages of SA-β-gal positive cells were calculated by counting more than 1,000 cells in random fields per cell line.
Cell proliferation assay and CV staining of cells. Cell proliferation assay were performed as described previously 42 . Briefly, cells were transfected with siRNAs for 24 h and seeded in 6-well cell culture dishes in triplicate at a density of 5,000 or 20,000 cells as indicated per well in 2 ml of medium supplemented with 10% FBS. The medium was changed every day. Cell number at the indicated time points was DOI: 10.1038/ncb2789
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